financetom
Business
financetom
/
Business
/
Eli Lilly Unusual Options Activity
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Eli Lilly Unusual Options Activity
Dec 11, 2024 7:24 AM

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly ( LLY ).

Looking at options history for Eli Lilly ( LLY ) we detected 11 trades.

If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 27% with bearish.

From the overall spotted trades, 4 are puts, for a total amount of $161,203 and 7, calls, for a total amount of $504,204.

Predicted Price Range

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $400.0 to $920.0 for Eli Lilly ( LLY ) during the past quarter.

Volume & Open Interest Trends

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

This data can help you track the liquidity and interest for Eli Lilly's ( LLY ) options for a given strike price.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's ( LLY ) whale activity within a strike price range from $400.0 to $920.0 in the last 30 days.

Eli Lilly Option Volume And Open Interest Over Last 30 Days

Significant Options Trades Detected:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
LLY CALL TRADE BEARISH 06/20/25 $83.2 $79.5 $79.5 $800.00 $151.0K 345 29
LLY CALL SWEEP BEARISH 06/20/25 $65.05 $62.55 $63.32 $840.00 $107.7K 606 17
LLY CALL TRADE BULLISH 01/17/25 $398.45 $392.45 $397.55 $400.00 $79.5K 374 0
LLY CALL TRADE BULLISH 06/20/25 $80.5 $79.5 $80.5 $800.00 $64.4K 345 2
LLY PUT TRADE BULLISH 01/17/25 $55.1 $52.3 $53.35 $830.00 $53.3K 1.0K 1

About Eli Lilly

Eli Lilly ( LLY ) is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

After a thorough review of the options trading surrounding Eli Lilly ( LLY ), we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Current Position of Eli Lilly

Trading volume stands at 120,979, with LLY's price down by -0.54%, positioned at $795.24.

RSI indicators show the stock to be is currently neutral between overbought and oversold.

Earnings announcement expected in 55 days.

Expert Opinions on Eli Lilly

In the last month, 2 experts released ratings on this stock with an average target price of $998.5.

Turn $1000 into $1270 in just 20 days?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.

* Reflecting concerns, an analyst from Wolfe Research lowers its rating to Outperform with a new price target of $1000.

* An analyst from B of A Securities has revised its rating downward to Buy, adjusting the price target to $997.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly ( LLY ) options trades with real-time alerts from Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Kimberly-Clark Maintains Quarterly Dividend at $1.22 a Share, Payable July 2 to Shareholders of Record June 7
--Kimberly-Clark Maintains Quarterly Dividend at $1.22 a Share, Payable July 2 to Shareholders of Record June 7
May 2, 2024
04:55 PM EDT, 05/02/2024 (MT Newswires) -- Price: 133.56, Change: -2.94, Percent Change: -2.15 ...
Emergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What's Going On With The Stock?
Emergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What's Going On With The Stock?
May 2, 2024
Emergent BioSolutions, Inc. ( EBS ) shares surged higher Thursday after the company announced operational changes to stabilize its financial position and reported first-quarter financial results. The Details: Emergent reported quarterly earnings of 59 cents per share, which beat the analyst consensus estimate of losses of 83 cents by 171.08%.  Quarterly sales clocked in at $300.4 million, which beat the...
Coterra Energy Q1 Adjusted Net Income, Revenue Fall; Shares Rise After Hours
Coterra Energy Q1 Adjusted Net Income, Revenue Fall; Shares Rise After Hours
May 2, 2024
04:54 PM EDT, 05/02/2024 (MT Newswires) -- Coterra Energy ( CTRA ) reported Q1 adjusted net income late Thursday of $0.51 a share, down from $0.87 a year earlier. Analysts polled by Capital IQ expected $0.41. Revenue in the quarter ended March 31 fell to $1.43 billion from $1.78 billion a year earlier. Analysts surveyed by Capital IQ expected $1.4...
Apple Fiscal Q2 Earnings Rise, Sales Fall; Boosts Dividend, Approves $110 Billion Share Buyback -- Shares Jump After Hours
Apple Fiscal Q2 Earnings Rise, Sales Fall; Boosts Dividend, Approves $110 Billion Share Buyback -- Shares Jump After Hours
May 2, 2024
04:55 PM EDT, 05/02/2024 (MT Newswires) -- Apple ( AAPL ) reported fiscal Q2 diluted earnings late Thursday of $1.53 a share, up from $1.52 a year earlier. Analysts surveyed by Capital IQ expected $1.50. Sales in the quarter ended March 30 were $90.75 billion, down from $94.84 billion a year earlier. Analysts surveyed by Capital IQ expected $90.45 billion....
Copyright 2023-2026 - www.financetom.com All Rights Reserved